Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ARP070101453Aexternal-prioritypatent/AR060362A1/en
Application filed by Takeda PharmaceuticalfiledCriticalTakeda Pharmaceutical
Publication of CR10676ApublicationCriticalpatent/CR10676A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
Se da a conocer un anticuerpo monoclonal humano dirigido contra una proteina que tiene una secuencia de aminoacidos que es la misma o sustancialmente la misma que la secuencia de aminoacidos ilustrada en la SEQ ID NO: 1 O 3, un peptido parcial de la proteina, o una sal de la proteina.A human monoclonal antibody directed against a protein having an amino acid sequence that is the same or substantially the same as the amino acid sequence illustrated in SEQ ID NO: 1 or 3, a partial peptide of the protein, or A salt of the protein.
CR10676A2006-10-062009-03-20
AGENT TO PREVENT / TREAT CANCER
CR10676A
(en)
monoclonal antibody, pharmaceutical composition, pharmaceutical combination, use of an antibody, use of a pharmaceutical composition and use of a pharmaceutical combination
Isolated tumor associated peptide (tumap); nucleic acid; expression vector; recombinant host cell comprising the peptide; method of producing the peptide; use to prepare a rare useful drug to treat cancer; pharmaceutical kit. (divisional application 201702407)
Fusion protein comprising a protein that cuts the beta amyloid peptide; pharmaceutical composition that includes it, and its use to prevent and / or treat diseases related to beta amyloid peptide.